Pomalidomide

Manufactured by MedChemExpress

Sourced in United States

Pomalidomide is a small molecule compound used as a laboratory research tool. It functions as a selective cereblon E3 ubiquitin ligase modulator. This product is intended for research purposes only and its suitability for any specific application should be validated by the user.

Automatically generated - may contain errors

Lab products found in correlation

Lenalidomide, by MedChemExpress (1 mentions) Ab2907, by Abcam (1 mentions) Bortezomib, by MedChemExpress (1 mentions) Ab24733, by Abcam (1 mentions) Cyclophosphamide, by MedChemExpress (1 mentions) Ab205719, by Abcam (1 mentions) Ab205718, by Abcam (1 mentions) Lsrfortessa x 20, by FlowJo (1 mentions) Lsrfortessa, by BD (1 mentions) Anti cd90 fluorescein isothiocyanate fitc, by BD (1 mentions) Anti granzyme b pe, by BD (1 mentions) Anti cd34 fitc, by BD (1 mentions)

3 protocols using pomalidomide

Evaluating C1q Receptor Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

WB was performed as previously described (17 (link)). Each experiment was repeated at least three times, with a representative experiment shown. The antibodies were as follows: anti-gC1qR antibody (Abcam, ab24733), anti-cC1qR antibody (Abcam, ab2907), anti-IGF2BP3 antibody (Abcam, ab177477), anti-β-actin antibody (Cell Signaling Technology, 4967S), and secondary horseradish-peroxidase-conjugated antibodies (Abcam, ab205719, ab205718). Five clinical drugs (bortezomib, ixazomib, lenalidomide, pomalidomide, and cyclophosphamide) were purchased from Med Chem Express, USA.

Xu J., Sun Y., Jiang J., Xu Z., Li J., Xu T, & Liu P. (2020). Globular C1q Receptor (gC1qR/p32/HABP1) Suppresses the Tumor-Inhibiting Role of C1q and Promotes Tumor Proliferation in 1q21-Amplified Multiple Myeloma. Frontiers in Immunology, 11, 1292.

+ Open protocol

+ Expand

HEK293T Transfection for Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

HEK293T cells were seeded at 300k cells per well of a 6-well plate. The next day cells were transfected with indicated reporter and any additional plasmids. 24 hour post-transfection cells were trypsinized, spun down at 300g for 5min, and resuspended in DMEM 10% fetal bovine serum. Cells were analyzed on either a BD Bioscience LSR Fortessa or LSR Fortessa X20at the University of California Berkeley flow cytometer facility, and FlowJo. GFP/mCherry ratios were determined from the median GFP and mCherry values. For TPEN and Pomalidomide treatment, TPEN was added at 2.5μM for 16hours and 10μM Pomalidomide (MedChemExpress, HY-10984) for 4 hours.

Manford A.G., Mena E.L., Shih K.Y., Gee C.L., McMinimy R., Martínez-González B., Sherriff R., Lew B., Zoltek M., Rodríguez-Pérez F., Woldesenbet M., Kuriyan J, & Rape M. (2021). Structural basis and regulation of the reductive stress response. Cell, 184(21), 5375-5390.e16.

+ Open protocol

+ Expand

Immune Checkpoint Modulation in Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-human PD-L1 antibody avelumab was purchased from MedChemExpress and this experiment was carried out with a standard dose of 20 μg/ml. Pomalidomide was purchased from MedChemExpress and this experiment was carried out with the standard dose of 20 μg/ml. The anti-human PD-L1 antibody avelumab and the immunomodulatory drug Pomalidomide were dissolved in dimethylsulfoxide (DMSO) and stored at -20℃.
Anti-PD-L1-phycoerythrin (PE) (no. 561787), anti-CD73-PB450 (no. 561260), anti-CD90-fluorescein isothiocyanate (FITC) (no. 555462), anti-CD105-allophycocyanin (APC) (no. 562408), anti-CD34-peridinin chlorophyll protein (PerCP) (no. 555821) and anti-CD45-APC-A750 (no. 557833) were purchased from BD Pharmingen (Franklin Lakes, NJ, USA).
Anti-CD3-PerCP (no. 6610008), anti-CD4-FITC (no. 35-0048), anti-CD8-PE (no. 6610025), anti-CD56-PE (no. Z6410020) and anti-PD-1-APC (no.6610897) were obtained from Beijing Tongsheng shidai Biotech Co., Ltd. Anti-CD34-FITC (no. 340430), anti-perforin-PE, anti-granzyme B-PE and isotype controls were obtained from BD Biosciences (San Jose, CA, USA).

Liu Z., Mi F., Han M., Tian M., Deng L., Meng N., Luo J, & Fu R. (2021). Bone marrow-derived mesenchymal stem cells inhibit CD8⁺ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma. Clinical and experimental immunology, 205(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!